eXoZymes 3Q 2026: EPS ($0.24) — 10-Q Summary
Czytanie zajmuje mniej niż 1 minutę
eXoZymes reported no operating income in the quarter, unchanged from a year earlier, while its net loss narrowed 2.1%. Higher research and development costs, driven by salaries, bonuses, stock-based compensation, laboratory expenses and reduced grant funding, were largely offset by a gain from remeasuring warrant liabilities.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Net income² | ($2.24M) | ($2.29M) | 2.1% |
| Diluted EPS³ | ($0.24) | ($0.27) | 11.1% |
² Reported as “Net loss”. ³ Reported as “Net loss per common share – basic and diluted”.
Business Highlights
- NCT pilot: The 100-liter pilot run converted 99% of feedstock into end product at 99.6% purity, the company said.
- Pipeline: AMBER is in scale-up, GRAS work and clinical studies; SAPPHIRE has begun scale-up, while AMETHYST completed proof of concept.
- DOE selection: In July, eXoZymes was selected for the Genesis Mission to develop AI-powered digital twins with Lawrence Berkeley National Laboratory.
- Funding outlook: Management said current working capital is insufficient to fund operations for 12 months from issuance and substantial doubt exists about going concern.
Original SEC Filing: EXOZYMES INC. [ EXOZ ] - 10-Q - Nov. 13, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.